Wed, Sep 3, 2014, 3:59 AM EDT - U.S. Markets open in 5 hrs 31 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • justarook04 justarook04 Jan 12, 2014 9:15 AM Flag

    From October 15th news (Leerink Swank) and the 10 companies covering INSM

    (Old news but reiterating good news):
    October 15, 2013
    10:10 am ET ... INSMED INCORPORATED (INSM 13.87) UP 0.83, INSMED (INSM)
    COMPLETES ARIKACE TRIAL. LEERINK SWANN REITERATES OUTPERFORM...
    Analyst Joseph Schwartz tells salesforce encouraged by INSM announcement
    that enrollment of TARGET-NTM (nontuberculous mycobacterial) is complete,
    co.'s initial powering assumptions have been validated. Notes INSM has
    powered trial at 80% to demonstrate a one-step change on sevenstep bacterial
    density scale, but his conversations with MEDACorp KOLs (key opinion leaders),
    analysis of limited clinical aerozolized Amikacin data generated in refractory
    NTM patients and animal models suggest Arikace's treatment effect could be
    much greater. Has $22 price target. M.Morrow

    Companies Offering Coverage (7 of which published RECs (3 Strong Buy, 4 Buy))
    Canaccord Genuity
    Collins Stewart LLC
    H.C.Wainwright & Co. ($25)
    JMP Securities ($25)
    Lazard Capital Markets
    Leerink Swann LLC ($22)
    Piper Jaffray Companies ($34)
    RBC Capital Markets
    UBS Investment Bank ($31)
    Wedbush Securities Inc.
    Wall Street Consensus Estimates (BUY)

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INSM
13.81-0.12(-0.86%)Sep 2 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.